Lantheus Holdings, Inc. (NASDAQ:LNTH – Get Free Report) saw unusually-high trading volume on Monday . Approximately 2,232,876 shares changed hands during mid-day trading, an increase of 131% from the previous session’s volume of 965,165 shares.The stock last traded at $102.0040 and had previously closed at $99.64.
Analysts Set New Price Targets
A number of equities analysts have commented on the stock. Mizuho reduced their target price on shares of Lantheus from $120.00 to $115.00 and set an “outperform” rating for the company in a report on Wednesday, July 29th. B. Riley Financial reaffirmed a “buy” rating on shares of Lantheus in a research report on Wednesday. Brookline Capital Markets downgraded shares of Lantheus from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. The Goldman Sachs Group reiterated a “neutral” rating and set a $94.00 price objective on shares of Lantheus in a research note on Thursday, May 7th. Finally, Citizens Jmp reissued a “market outperform” rating and set a $115.00 target price on shares of Lantheus in a research report on Monday, June 29th. Seven equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $109.71.
Get Our Latest Stock Analysis on Lantheus
Lantheus Stock Up 2.2%
Lantheus (NASDAQ:LNTH – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.25 by $0.21. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The business had revenue of $377.33 million during the quarter, compared to the consensus estimate of $354.48 million. During the same quarter last year, the company earned $1.53 earnings per share. The company’s quarterly revenue was up 1.2% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, equities analysts predict that Lantheus Holdings, Inc. will post 4.5 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Lantheus
Several institutional investors and hedge funds have recently made changes to their positions in LNTH. Versant Capital Management Inc increased its holdings in Lantheus by 33.0% in the 2nd quarter. Versant Capital Management Inc now owns 588 shares of the medical equipment provider’s stock worth $65,000 after buying an additional 146 shares during the period. Abel Hall LLC boosted its holdings in shares of Lantheus by 4.6% in the 1st quarter. Abel Hall LLC now owns 3,915 shares of the medical equipment provider’s stock valued at $297,000 after acquiring an additional 172 shares during the last quarter. Smartleaf Asset Management LLC boosted its holdings in shares of Lantheus by 63.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock valued at $34,000 after acquiring an additional 197 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Lantheus by 6.4% in the second quarter. GAMMA Investing LLC now owns 3,348 shares of the medical equipment provider’s stock worth $371,000 after acquiring an additional 202 shares during the period. Finally, Blue Trust Inc. increased its stake in shares of Lantheus by 30.3% in the fourth quarter. Blue Trust Inc. now owns 990 shares of the medical equipment provider’s stock worth $66,000 after acquiring an additional 230 shares during the period. 99.06% of the stock is currently owned by institutional investors and hedge funds.
About Lantheus
Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.
The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.
Featured Stories
- Five stocks we like better than Lantheus
- The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
- TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?
- AST SpaceMobile Sets Launch Date Ahead of Key Q2 Earnings Test
- 5 Tech Stocks Holding Their Ground Through the AI Trade Pullback
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.
